Matthias Miederer1, Stefanie Pektor1, Isabelle Miederer1, Nicole Bausbacher1, Isabell Sofia Keil2, Hossam Hefesha3, Heinrich Haas3, Ugur Sahin2,3, Mustafa Diken4,5. 1. Department of Nuclear Medicine, University Medical Center of Johannes Gutenberg University, Mainz, Germany. 2. TRON - Translational Oncology at the University Medical Center, Johannes Gutenberg University Mainz gGmbH, Mainz, Germany. 3. Biopharmaceutical New Technologies (BioNTech) SE, Mainz, Germany. 4. TRON - Translational Oncology at the University Medical Center, Johannes Gutenberg University Mainz gGmbH, Mainz, Germany. mustafa.diken@tron-mainz.de. 5. Biopharmaceutical New Technologies (BioNTech) SE, Mainz, Germany. mustafa.diken@tron-mainz.de.
Abstract
BACKGROUND: RNA-based vaccination strategies tailoring immune response to specific reactions have become an important pillar for a broad range of applications. Recently, the use of lipid-based nanoparticles opened the possibility to deliver RNA to specific sites within the body, overcoming the limitation of rapid degradation in the bloodstream. Here, we have investigated whether small animal PET/MRI can be employed to image the biodistribution of RNA-encoded protein. For this purpose, a reporter RNA coding for the sodium-iodide-symporter (NIS) was in vitro transcribed in cell lines and evaluated for expression. RNA-lipoplex nanoparticles were then assembled by complexing RNA with liposomes at different charge ratios, and functional NIS protein translation was imaged and quantified in vivo and ex vivo by Iodine-124 PET upon intravenous administration in mice. RESULTS: NIS expression was detected on the membrane of two cell lines as early as 6 h after transfection and gradually decreased over 48 h. In vivo and ex vivo PET/MRI of anionic spleen-targeting or cationic lung-targeting NIS-RNA lipoplexes revealed a visually detectable rapid increase of Iodine-124 uptake in the spleen or lung compared to control-RNA-lipoplexes, respectively, with minimal background in other organs except from thyroid, stomach and salivary gland. CONCLUSIONS: The strong organ selectivity and high target-to-background acquisition of NIS-RNA lipoplexes indicate the feasibility of small animal PET/MRI to quantify organ-specific delivery of RNA.
BACKGROUND: RNA-based vaccination strategies tailoring immune response to specific reactions have become an important pillar for a broad range of applications. Recently, the use of lipid-based nanoparticles opened the possibility to deliver RNA to specific sites within the body, overcoming the limitation of rapid degradation in the bloodstream. Here, we have investigated whether small animal PET/MRI can be employed to image the biodistribution of RNA-encoded protein. For this purpose, a reporter RNA coding for the sodium-iodide-symporter (NIS) was in vitro transcribed in cell lines and evaluated for expression. RNA-lipoplex nanoparticles were then assembled by complexing RNA with liposomes at different charge ratios, and functional NIS protein translation was imaged and quantified in vivo and ex vivo by Iodine-124 PET upon intravenous administration in mice. RESULTS:NIS expression was detected on the membrane of two cell lines as early as 6 h after transfection and gradually decreased over 48 h. In vivo and ex vivo PET/MRI of anionic spleen-targeting or cationic lung-targeting NIS-RNA lipoplexes revealed a visually detectable rapid increase of Iodine-124 uptake in the spleen or lung compared to control-RNA-lipoplexes, respectively, with minimal background in other organs except from thyroid, stomach and salivary gland. CONCLUSIONS: The strong organ selectivity and high target-to-background acquisition of NIS-RNA lipoplexes indicate the feasibility of small animal PET/MRI to quantify organ-specific delivery of RNA.
Entities:
Keywords:
Cancer immunotherapy; Cancer vaccination; Iodine-124; NIS; PET/MRI; RNA vaccine
Authors: Sebastian Lehner; Cajetan Lang; Georgios Kaissis; Andrei Todica; Mathias Johannes Zacherl; Guido Boening; Christine Spitzweg; Nadja Herbach; Wolfgang-Michael Franz; Bernd Joachim Krause; Gustav Steinhoff; Peter Bartenstein; Marcus Hacker; Robert David Journal: Mol Imaging Biol Date: 2015-12 Impact factor: 3.488
Authors: Stephan Grabbe; Heinrich Haas; Mustafa Diken; Lena M Kranz; Peter Langguth; Ugur Sahin Journal: Nanomedicine (Lond) Date: 2016-10 Impact factor: 5.307
Authors: Ugur Sahin; Petra Oehm; Evelyna Derhovanessian; Robert A Jabulowsky; Mathias Vormehr; Maike Gold; Daniel Maurus; Doreen Schwarck-Kokarakis; Andreas N Kuhn; Tana Omokoko; Lena M Kranz; Mustafa Diken; Sebastian Kreiter; Heinrich Haas; Sebastian Attig; Richard Rae; Katarina Cuk; Alexandra Kemmer-Brück; Andrea Breitkreuz; Claudia Tolliver; Janina Caspar; Juliane Quinkhardt; Lisa Hebich; Malte Stein; Alexander Hohberger; Isabel Vogler; Inga Liebig; Stephanie Renken; Julian Sikorski; Melanie Leierer; Verena Müller; Heidrun Mitzel-Rink; Matthias Miederer; Christoph Huber; Stephan Grabbe; Jochen Utikal; Andreas Pinter; Roland Kaufmann; Jessica C Hassel; Carmen Loquai; Özlem Türeci Journal: Nature Date: 2020-07-29 Impact factor: 49.962
Authors: Thomas Groot-Wassink; Eric O Aboagye; Yaohe Wang; Nicholas R Lemoine; Andrew J Reader; Georges Vassaux Journal: Mol Ther Date: 2004-03 Impact factor: 11.454
Authors: Lena M Kranz; Mustafa Diken; Heinrich Haas; Sebastian Kreiter; Carmen Loquai; Kerstin C Reuter; Martin Meng; Daniel Fritz; Fulvia Vascotto; Hossam Hefesha; Christian Grunwitz; Mathias Vormehr; Yves Hüsemann; Abderraouf Selmi; Andreas N Kuhn; Janina Buck; Evelyna Derhovanessian; Richard Rae; Sebastian Attig; Jan Diekmann; Robert A Jabulowsky; Sandra Heesch; Jessica Hassel; Peter Langguth; Stephan Grabbe; Christoph Huber; Özlem Türeci; Ugur Sahin Journal: Nature Date: 2016-06-01 Impact factor: 49.962
Authors: Sarah Urnauer; Andrea M Müller; Christina Schug; Kathrin A Schmohl; Mariella Tutter; Nathalie Schwenk; Wolfgang Rödl; Stephan Morys; Michael Ingrisch; Jens Bertram; Peter Bartenstein; Dirk-André Clevert; Ernst Wagner; Christine Spitzweg Journal: Oncotarget Date: 2017-09-16